| (AstraZeneca) D910DC00001 / EMERALD-2 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation. | Meyers, Dr Brandon | Open to recruitment | NCT03847428 |
| (CCTG) CO.29 / DYNAMIC III | Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC III) | Goffin, Dr John | Open to recruitment | ACTRN12617001566325 |
| (CCTG) CRC.9 / NRG-GI005 | Phase II/III Study of Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) | Meyers, Dr Brandon | Open to recruitment | NCT04068103 |
| (Merck) MK-7902-015 / LEAP 015 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma. | Juergens, Dr Rosalyn | Open to recruitment | NCT04662710 |
| (Roche) MO42541 / IMbrave251 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATEDWITH ATEZOLIZUMAB AND BEVACIZUMAB | Meyers, Dr Brandon | Open to recruitment | NCT04770896 |
| (CCTG) CO.21 / CHALLENGE | A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) | Goffin, Dr John | Suspended/On hold | NCT00819208 |
Find a Trial
Contact Us